
Fifty-five types of medicine listed in China's third-round centralized drug-procurement program have become available in public hospitals across the country at much lower prices, the National Healthcare Security Administration said Thursday.
The medicines, with an average price cut of 53 percent, include those widely prescribed for diabetes, high blood pressure, infections and cancers, the administration said.
China initiated a trial of the centralized drug procurement in 2019. Since then, three rounds of the procurement have covered 112 varieties of medicine, with their average price down 54 percent.
Based on the reimbursement rate of 60 percent, the program is estimated to save 21.6 billion yuan (about 3.34 billion U.S. dollars) for public hospital patients and 32.3 billion yuan for the medical insurance fund annually, the administration said.
According to Prof. Hu Shanlian at the School of Public Health of Fudan University, the program will lead to reduction in prices of drugs not yet included in the program. This will have a ripple effect and could see pharmacies and private medical institutions lower drug prices, Hu said.
More medicines with large demands and high prices are expected to be covered by the centralized drug-procurement program, Hu added.
Fire brigade in Shanghai holds group wedding
Tourists enjoy ice sculptures in Datan Town, north China
Sunset scenery of Dayan Pagoda in Xi'an
Tourists have fun at scenic spot in Nanlong Town, NW China
Harbin attracts tourists by making best use of ice in winter
In pics: FIS Alpine Ski Women's World Cup Slalom
Black-necked cranes rest at reservoir in Lhunzhub County, Lhasa
China's FAST telescope will be available to foreign scientists in April
"She power" plays indispensable role in poverty alleviation
Top 10 world news events of People's Daily in 2020
Top 10 China news events of People's Daily in 2020
Top 10 media buzzwords of 2020
Year-ender:10 major tourism stories of 2020
No interference in Venezuelan issues
Biz prepares for trade spat
Broadcasting Continent
Australia wins Chinese CEOs as US loses